1. a positive covid-19 result (pcr or antigen test) within 30 days of screening. 2. presence of typical covid-19 symptoms which cannot be explained by another underlying condition (fever \>38°c, oxygen saturation (spo2) below 93%, dyspnea, difficulty breathing, chills, ageusia, anosmia, cough, myalgia) in the past 48 hours prior to screening. 3. hypersensitivity to any component of ibio123 4. participants who have been previously administered ibio123. 5. have received treatment with a sars-cov-2 specific monoclonal antibody 6. have participated, within the last 30 days, in a clinical study involving an investigational intervention. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. 7. are pregnant or breast feeding 8. are investigator site personnel directly affiliated with this study.

1. a positive covid-19 result (pcr or antigen test) within 30 days of screening. 2. presence of typical covid-19 symptoms which cannot be explained by another underlying condition (fever \>38°c, oxygen saturation (spo2) below 93%, dyspnea, difficulty breathing, chills, ageusia, anosmia, cough, myalgia) in the past 48 hours prior to screening. 3. hypersensitivity to any component of ibio123 4. participants who have been previously administered ibio123. 5. have received treatment with a sars-cov-2 specific monoclonal antibody 6. have participated, within the last 30 days, in a clinical study involving an investigational intervention. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. 7. are pregnant or breast feeding 8. are investigator site personnel directly affiliated with this study.

a positive covid-19 result (pcr or antigen test) within 30 days of screening. presence of typical covid-19 symptoms which cannot be explained by another underlying condition (fever >38°c, oxygen saturation (spo2) below 93%, dyspnea, difficulty breathing, chills, ageusia, anosmia, cough, myalgia) in the past 48 hours prior to screening. hypersensitivity to any component of ibio123 participants who have been previously administered ibio123. have received treatment with a sars-cov-2 specific monoclonal antibody have participated, within the last 30 days, in a clinical study involving an investigational intervention. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. are pregnant or breast feeding are investigator site personnel directly affiliated with this study.

a positive covid-19 result (pcr or antigen test) within 30 days of screening. presence of typical covid-19 symptoms which cannot be explained by another underlying condition (fever >38°c, oxygen saturation (spo2) below 93%, dyspnea, difficulty breathing, chills, ageusia, anosmia, cough, myalgia) in the past 48 hours prior to screening. hypersensitivity to any component of ibio123 participants who have been previously administered ibio123. have received treatment with a sars-cov-2 specific monoclonal antibody have participated, within the last 30 days, in a clinical study involving an investigational intervention. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. are pregnant or breast feeding are investigator site personnel directly affiliated with this study.

a positive covid-19 result (pcr or antigen test) within 30 days of screening. presence of typical covid-19 symptoms which cannot be explained by another underlying condition (fever >38°c, spo2 below 93%, dyspnea, difficulty breathing, chills, ageusia, anosmia, cough, myalgia) in the past 48 hours prior to screening. hypersensitivity to any component of ibio123 participants who have been previously administered ibio123. have received treatment with a sars-cov-2 specific monoclonal antibody have participated, within the last 30 days, in a clinical study involving an investigational intervention. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. are pregnant or breast feeding are investigator site personnel directly affiliated with this study.

a positive covid-19 result (pcr or antigen test) within 30 days of screening. presence of typical covid-19 symptoms which cannot be explained by another underlying condition (fever >38°c, spo2 below 93%, dyspnea, difficulty breathing, chills, ageusia, anosmia, cough, myalgia) in the past 48 hours prior to screening. hypersensitivity to any component of ibio123 participants who have been previously administered ibio123. have received treatment with a sars-cov-2 specific monoclonal antibody have participated, within the last 30 days, in a clinical study involving an investigational intervention. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. are pregnant or breast feeding are investigator site personnel directly affiliated with this study.